Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Petra Hillmann"'
Autor:
Justin S. Antony, Pascale Birrer, Claudia Bohnert, Sina Zimmerli, Petra Hillmann, Hervé Schaffhauser, Christine Hoeflich, Andreas Hoeflich, Ramzi Khairallah, Andreas T. Satoh, Isabelle Kappeler, Isabel Ferreira, Klaas P. Zuideveld, Friedrich Metzger
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 34, Iss , Pp 102055- (2023)
Insulin-like growth factor I (IGF-I) is a growth-promoting anabolic hormone that fosters cell growth and tissue homeostasis. IGF-I deficiency is associated with several diseases, including growth disorders and neurological and musculoskeletal disease
Externí odkaz:
https://doaj.org/article/9c7a20e7616f432288f59c0d27bd4194
Autor:
Luca Aresu, Serena Ferraresso, Laura Marconato, Luciano Cascione, Sara Napoli, Eugenio Gaudio, Ivo Kwee, Chiara Tarantelli, Andrea Testa, Chiara Maniaci, Alessio Ciulli, Petra Hillmann, Thomas Bohnacker, Matthias P. Wymann, Stefano Comazzi, Massimo Milan, Fulvio Riondato, Giulia Dalla Rovere, Mery Giantin, Diana Giannuzzi, Francesco Bertoni
Publikováno v:
Haematologica, Vol 104, Iss 6 (2019)
Externí odkaz:
https://doaj.org/article/df8e7002c3f442f0a88084a02154e353
Autor:
Petra Hillmann, Doriano Fabbro
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 22, p 5792 (2019)
The phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway has been implicated as a cancer target. Big pharma players and small companies have been developing small molecule inhibitors of PI3K and/or mTOR since th
Externí odkaz:
https://doaj.org/article/b6def8ed15a1422292145255b5be80d3
Autor:
Chiara Tarantelli, Eugenio Gaudio, Petra Hillmann, Filippo Spriano, Giulio Sartori, Luca Aresu, Luciano Cascione, Denise Rageot, Ivo Kwee, Florent Beaufils, Emanuele Zucca, Anastasios Stathis, Matthias P. Wymann, Vladimir Cmiljanovic, Doriano Fabbro, Francesco Bertoni
Publikováno v:
Cancers, Vol 11, Iss 6, p 775 (2019)
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical
Externí odkaz:
https://doaj.org/article/5c18c40918424563bfca6e8df465cdf3
Autor:
Francesco Bertoni, Doriano Fabbro, Vladimir Cmiljanovic, Emanuele Zucca, Andreas Wicki, Matthias P. Wymann, Massimo Broggini, Georg Stussi, Anastasios Stathis, Davide Rossi, Valter Gattei, Monica Taborelli, Antonella Zucchetto, Francesca Maria Rossi, Barbara Dossena, Alexander Sele, Denise Rageot, Reto Ritschard, Florent Beaufils, Roberta Bordone Pittau, Laura Carrassa, Francesca Guidetti, Elena Bernasconi, Filippo Spriano, Luciano Cascione, Andrea Rinaldi, Petra Hillmann, Ivo Kwee, Alberto J. Arribas, Eugenio Gaudio, Chiara Tarantelli
PQR309 activity, combinations of PQR309 with additional drugs, BCL2, MYC and TP53 status in lymphoma cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f1eeed7d4b356b5a4fbe61a0871ceb9
https://doi.org/10.1158/1078-0432.22463270.v1
https://doi.org/10.1158/1078-0432.22463270.v1
Autor:
Francesco Bertoni, Doriano Fabbro, Vladimir Cmiljanovic, Emanuele Zucca, Andreas Wicki, Matthias P. Wymann, Massimo Broggini, Georg Stussi, Anastasios Stathis, Davide Rossi, Valter Gattei, Monica Taborelli, Antonella Zucchetto, Francesca Maria Rossi, Barbara Dossena, Alexander Sele, Denise Rageot, Reto Ritschard, Florent Beaufils, Roberta Bordone Pittau, Laura Carrassa, Francesca Guidetti, Elena Bernasconi, Filippo Spriano, Luciano Cascione, Andrea Rinaldi, Petra Hillmann, Ivo Kwee, Alberto J. Arribas, Eugenio Gaudio, Chiara Tarantelli
Purpose: Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacologic inhibition of the PI3K/mTOR pathway has shown activity in lymphoma patients. Here, we extensively characterized the in vitro and in viv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d77cd161db08446658401a98858de92
https://doi.org/10.1158/1078-0432.c.6525353
https://doi.org/10.1158/1078-0432.c.6525353
Autor:
Francesco Bertoni, Doriano Fabbro, Vladimir Cmiljanovic, Emanuele Zucca, Andreas Wicki, Matthias P. Wymann, Massimo Broggini, Georg Stussi, Anastasios Stathis, Davide Rossi, Valter Gattei, Monica Taborelli, Antonella Zucchetto, Francesca Maria Rossi, Barbara Dossena, Alexander Sele, Denise Rageot, Reto Ritschard, Florent Beaufils, Roberta Bordone Pittau, Laura Carrassa, Francesca Guidetti, Elena Bernasconi, Filippo Spriano, Luciano Cascione, Andrea Rinaldi, Petra Hillmann, Ivo Kwee, Alberto J. Arribas, Eugenio Gaudio, Chiara Tarantelli
Supplementary figures, table legends, Table S1, S9 Figure S1. In vitro antitumor activity of the dual PI3K/mTOR inhibitor apitolisib and its correlation with PQR309. Figure S2. Antitumor In vivo activity of PQR309 in the treatment of RI-1 and SU-DHL-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44857e5ceee1661ea892f16d14f85911
https://doi.org/10.1158/1078-0432.22463273.v1
https://doi.org/10.1158/1078-0432.22463273.v1
Autor:
Wolfgang Löscher, Denise Rageot, Rohitha Sriramaratnam, Erhan Keles, Petra Hillmann, Matthias Hamburger, Andrea Treyer, Doriano Fabbro, Florent Beaufils, Paul Hebeisen, Anna Melone, Matthias P. Wymann, Martina De Pascale, Lukas Bissegger, Chiara Borsari, Thomas Bohnacker
Publikováno v:
Journal of Medicinal Chemistry. 63:13595-13617
The mechanistic target of rapamycin (mTOR) pathway is hyperactivated in cancer and neurological disorders. Rapalogs and mTOR kinase inhibitors (TORKi) have recently been applied to alleviate epileptic seizures in tuberous sclerosis complex (TSC). Her
Autor:
Chiara Borsari, Doriano Fabbro, Petra Hillmann, Florent Beaufils, Thomas Bohnacker, Matthias P. Wymann, Denise Rageot, Ivan Buslov, Erhan Keles, Alexander M. Sele, Anna Melone, Paul Hebeisen
Publikováno v:
ACS Medicinal Chemistry Letters
The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is a critical regulator of cell growth and is frequently hyperactivated in cancer. Therefore, PI3K inhibitors represent a valuable asset in cancer therapy. Herein we
Autor:
Petra Hillmann, Justin A. Selvaraj, Sina E. Zimmerli, Pascale G. Birrer, Claudia C. Bohnert, Klaas P. Zuideveld, Stefan J. Scherer, Friedrich Metzger
Publikováno v:
Cancer Research. 82:1081-1081
Combination therapy is implicated for many oncological indications to circumvent resistance mechanisms that reduce efficacy of targeted drugs. In recent years, mRNA has been successfully utilized preclinically to deliver cytokines to tumors locally a